scholarly article | Q13442814 |
P50 | author | Ernesto Moreno | Q54271568 |
Enrique Montero | Q89109529 | ||
Patricia Hernandez | Q89109531 | ||
P2093 | author name string | R Torres | |
J P Martínez | |||
A M López | |||
M V Hernández | |||
J A Gómez | |||
P C Rodríguez | |||
C Viada | |||
C Molinero | |||
D M Prada | |||
I M Hernández | |||
J M Milera | |||
L E Aira | |||
Y Avila | |||
Y Barrese | |||
Y Reyes | |||
P2860 | cites work | 6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland | Q42732008 |
A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas. | Q42799131 | ||
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D | Q43205844 | ||
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report | Q45180236 | ||
Anemia and renal function in patients with rheumatoid arthritis. | Q46514198 | ||
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 | ||
Health-related quality of life in fibromyalgia patients: a comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. | Q48367538 | ||
Aberrant expression of CD6 on B-cell subsets from patients with Sjögren's syndrome. | Q51038812 | ||
Humanization of Predicted T-Cell Epitopes Reduces the Immunogenicity of Chimeric Antibodies: New Evidence Supporting a Simple Method | Q51820107 | ||
Towards the definition of a chimpanzee and human conserved CD6 domain 1 epitope recognized by T1 monoclonal antibody. | Q52839720 | ||
Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. | Q54145863 | ||
T cell activation regulates CD6 alternative splicing by transcription dynamics and SRSF1. | Q54348065 | ||
Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin‐17A production | Q54406138 | ||
Evidence for the expression of a second CD6 ligand by synovial fibroblasts | Q60975375 | ||
High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome | Q74523535 | ||
Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis | Q77123551 | ||
Cytokine-regulated expression of activated leukocyte cell adhesion molecule (CD166) on monocyte-lineage cells and in rheumatoid arthritis synovium | Q77742364 | ||
CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease | Q78085988 | ||
Role of Th17 cells in human autoimmune arthritis | Q84488292 | ||
Phenotypical characterization of human Th17 cells unambiguously identified by surface IL-17A expression | Q84754845 | ||
Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci | Q24656799 | ||
Leukotrienes, mast cells, and T cells | Q24795112 | ||
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis | Q28728734 | ||
Restoring the balance: immunotherapeutic combinations for autoimmune disease | Q33555986 | ||
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab | Q33573621 | ||
Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 | ||
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis | Q34315745 | ||
CD6 as a therapeutic target in autoimmune diseases: successes and challenges. | Q34337963 | ||
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial | Q34530459 | ||
Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review | Q34574374 | ||
A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients | Q35586904 | ||
CD6 attenuates early and late signaling events, setting thresholds for T-cell activation | Q35818957 | ||
Social aspects of living with rheumatoid arthritis: a qualitative descriptive study in Soweto, South Africa - a low resource context | Q36817685 | ||
Immunological evaluation of rheumatoid arthritis patients treated with itolizumab | Q37138277 | ||
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review | Q37158791 | ||
A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis | Q37390483 | ||
Randomized controlled trial design in rheumatoid arthritis: the past decade | Q37397646 | ||
Long-term outcomes of rheumatoid arthritis | Q37431424 | ||
Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels. An observational study | Q38123838 | ||
Emerging cell and cytokine targets in rheumatoid arthritis | Q38161794 | ||
Immunocompetent properties of human osteoblasts: interactions with T lymphocytes | Q38317712 | ||
CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction | Q38341487 | ||
Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses. | Q38509507 | ||
Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab | Q38722576 | ||
Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study | Q39876671 | ||
Expression and characterization of a novel CD6 ligand in cells derived from joint and epithelial tissues | Q40495317 | ||
P433 | issue | 2 | |
P921 | main subject | rheumatoid arthritis | Q187255 |
lymphopenia | Q485831 | ||
phase I clinical trial | Q5452194 | ||
P304 | page(s) | 229-239 | |
P577 | publication date | 2017-11-16 | |
P1433 | published in | Clinical and Experimental Immunology | Q15716708 |
P1476 | title | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial | |
P478 | volume | 191 |